Status:
COMPLETED
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Conditions:
Epithelial Ovarian Cancer
Extraovarian Peritoneal Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for f...
Detailed Description
This is a non-randomized, single-arm, Phase II trial. Selected patients with advanced-stage epithelial ovarian cancers who have no reasonable chance of cure using standard regimens, or who will not re...
Eligibility Criteria
Inclusion
- Able to provide informed consent
- Not on Immune modulating drugs
- Life expectancy less than 6 months
Exclusion
- Unable to tolerate phlebotomy
- Germ cell or stromal cell cancers of the ovaries
- Active autoimmune disease
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00880360
Start Date
February 1 2007
End Date
April 1 2010
Last Update
March 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CTRC at UTHSCSA
San Antonio, Texas, United States, 78229